Fibromyalgia: Diagnosis Criteria, Treatment Options, and Ongoing Research

A Real Disease That Took Decades to Be Taken Seriously

Fibromyalgia was absent from the medical lexicon until 1976, when Dr. P.K. Hench coined the term, and remained widely dismissed as psychosomatic or a "wastebasket" diagnosis for unexplained symptoms for another two decades. Today, neuroimaging studies using functional MRI and PET scanning have revealed measurable differences in central pain processing in fibromyalgia patients, and the condition is recognized by the American College of Rheumatology (ACR), the FDA (which has approved three drugs for it), and major pain societies worldwide as a distinct neurological disorder of central sensitization. Approximately 4 million Americans — roughly 2% of the population — have fibromyalgia, with women diagnosed at 2–3 times the rate of men, though that ratio may partly reflect diagnostic bias.

Fibromyalgia is not in the joints. It is in the central nervous system.

Understanding Central Sensitization

The core mechanism of fibromyalgia is central sensitization: the spinal cord and brain amplify incoming pain signals, lower the threshold for pain activation, and expand the area perceived as painful. Functional MRI studies have consistently shown that fibromyalgia patients demonstrate stronger brain responses to standardized pressure stimuli than healthy controls, with activation in pain-processing regions (insula, anterior cingulate cortex, secondary somatosensory cortex) at stimulus intensities that do not activate these areas in controls. The descending pain inhibitory pathways — normally dampening nociceptive input — show reduced function, and conditioned pain modulation (CPM), a standard test of this inhibitory capacity, is reliably impaired in fibromyalgia.

These neurophysiological abnormalities explain why fibromyalgia pain is real, why standard anti-inflammatory approaches fail, and why centrally acting medications are more effective than peripheral analgesics.

Diagnostic Criteria: The 2016 ACR Revision

The original 1990 ACR criteria required bilateral widespread pain plus tenderness at 11 of 18 specific tender points — an exam-dependent measure criticized for poor reproducibility. The 2010/2011 and subsequently revised 2016 ACR criteria eliminated tender point examination, replacing it with two symptom-based measures:

• Widespread Pain Index (WPI): Count of body areas in which the patient has had pain over the last week across 19 defined regions; score 0–19
• Symptom Severity Scale (SSS): Scores fatigue, waking unrefreshed, and cognitive symptoms (each 0–3) plus severity of additional somatic symptoms; score 0–12

Diagnosis requires WPI ≥7 and SSS ≥5, or WPI 4–6 and SSS ≥9, with symptoms present at a similar level for at least 3 months, and no other disorder that would otherwise explain the pain. The 2016 criteria also require that a fibromyalgia diagnosis not be excluded by another diagnosis — recognizing that fibromyalgia commonly coexists with rheumatoid arthritis, lupus, and other conditions rather than being an alternative explanation for symptoms.

FDA-Approved Medications

Three drugs hold FDA approval specifically for fibromyalgia:

Response rates are modest in absolute terms — roughly 30–35% of patients achieve at least 30% pain reduction — but are meaningful given the absence of effective alternatives for a centrally mediated pain syndrome. Tricyclic antidepressants (amitriptyline, cyclobenzaprine) are off-label but commonly used, particularly at low doses for sleep, and show efficacy in meta-analyses. Gabapentin is frequently used off-label by analogy with pregabalin.

Exercise: The Single Most Evidenced Intervention

Aerobic exercise is the most consistently supported treatment for fibromyalgia across the evidence base. A 2017 Cochrane review of aerobic exercise in fibromyalgia identified 13 RCTs and found moderate-quality evidence that aerobic exercise improves health-related quality of life (standardized mean difference 0.35), pain (SMD 0.29), and physical function, with low-quality evidence for fatigue and sleep. Resistance training shows comparable benefits in direct comparison trials. Exercise dosing recommendations:

• Starting intensity should be low to avoid post-exertional symptom flares — often a major barrier to initiation
• Gradually increasing aerobic activity to 150 minutes per week of moderate intensity is the long-term target
• Water-based (aquatic) exercise is particularly well-tolerated for patients with pain-limited land exercise capacity
• Consistency matters more than intensity; daily gentle movement outperforms infrequent intense exercise in fibromyalgia populations

Psychological and Multimodal Treatment

Cognitive behavioral therapy, acceptance and commitment therapy (ACT), and mindfulness-based cognitive therapy all show efficacy in fibromyalgia for pain-related catastrophizing, disability, and quality of life, though effect sizes are modest for pain intensity itself. Multidisciplinary pain programs combining supervised exercise, psychological treatment, and pharmacotherapy produce the most consistent and durable improvements in functional outcomes — superior to any single-modality approach.

Emerging Research Directions

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.